Effective reduction of plasma LDL levels by LDL apheresis in familial defective apolipoprotein B-100

Atherosclerosis. 1992 Aug;95(2-3):231-4. doi: 10.1016/0021-9150(92)90026-d.

Abstract

The clinical response to long-term reduction of the plasma LDL cholesterol concentration was studied in a man with severe coronary artery disease associated with familial defective apolipoprotein B-100 (FDB). Plasma exchange repeated at 2-week intervals, combined with lipid-lowering drugs, led to remission of angina and improved exercise test performance. A similar clinical response was achieved after LDL apheresis with dextran sulphate columns repeated once every 2 weeks in combination with drug treatment. The reduction in plasma LDL cholesterol level brought about by LDL apheresis was at least as marked in the FDB patient as in 5 patients with familial hypercholesterolaemia. We conclude that FDB patients with coronary artery disease may derive clinical benefit from prolonged reduction of their plasma cholesterol levels and that LDL containing apo B-100 in which arginine at position 3500 is replaced by glutamine is removed from plasma by dextran sulphate columns as efficiently as is normal LDL.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoprotein B-100
  • Apolipoproteins B / chemistry*
  • Blood Component Removal*
  • Cholesterol, LDL / blood*
  • Coronary Disease / blood
  • Coronary Disease / therapy
  • Female
  • Hematologic Diseases / blood
  • Hematologic Diseases / therapy*
  • Heterozygote
  • Humans
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / genetics
  • Hyperlipoproteinemia Type II / therapy
  • Male
  • Middle Aged

Substances

  • Apolipoprotein B-100
  • Apolipoproteins B
  • Cholesterol, LDL